qed-clinical.com [email protected] +44 (0)1908 251 4802
Agenda
Partnering Excellence
� QED – Powerful Partnership
� Global and Local
� Capacity by Region and Coordination
� QED – Quality, Efficiency, Delivery
� QED Global Study Experience
� Project Management Expertise
QED India
� QED India – The Asia Pacific Hub
� QED India Engagement in Nine Months
� QED India - Services
� QED India Staff Experience
� Why QED India?
The QED Difference
OrphanReach
qed-clinical.com [email protected] +44 (0)1908 251 4804
QED: Powerful Partnership
Established in 2002 having 10 years of global partnering experience
Operational Senior Management with more than 26 years experience in clinical research
Over 1,100 clinical experts world-wide
— More than 120 experienced Project Managers
— Over 450 locally based CRAs
Successful delivery of more than 2,700 studies across most therapeutic areas
Proven Specialist Partnering model with focus on customer service
qed-clinical.com [email protected] +44 (0)1908 251 4805
Global & Local
Global
Capacity
Local
Knowledge
Patient
Access &
Retention
Regulatory
Insight
qed-clinical.com [email protected] +44 (0)1908 251 4806
United States and Canada
South AmericaArgentina
Brazil
Chile
Mexico
Bolivia
Western Europe (WEU)
UK
Belgium
France
Germany
Austria
Switzerland
Italy
Netherlands
Portugal
Spain
Russia
Central and Eastern Europe (CEE)
Belarus
Bulgaria
Croatia and Slovenia
Czech Republic
Slovakia
Hungary
Macedonia
Poland
Romania
Serbia and Montenegro
Slovenia
Turkey
Greece
Ukraine
The Baltics
Estonia
Latvia
Lithuania
Nordic / Scandinavia
Denmark
Finland
Sweden
Norway
Africa and Middle East
Egypt
Israel
Lebanon
Macedonia
South Africa
United Arab Emirates
Qatar
Bahrain
Oman
Kuwait
Jordan
Iran
Asia
India
China
Vietnam
Sri Lanka
Bangladesh
Philippines
Japan
Taiwan
Australia
Malaysia
New Zealand
South Korea
Singapore
Thailand
Capacity by Region
qed-clinical.com [email protected] +44 (0)1908 251 4807
Regional Coordination
On-going/ previous Start-up phase
QED European
Hub
QED Asia
Pacific Hub
QED North
American
Hub
qed-clinical.com [email protected] +44 (0)1908 251 4808
Partnering Transformation
The CRO has truly come of age as a real partner and all eyes are on the critical question of
delivery of promises on time and on budget….
The goals for paterning have not changed but the way of delivering must evolve.....
Delivery
qed-clinical.com [email protected] +44 (0)1908 251 48010
Meeting Quality Standards
• Success is dependent on delivering project goals on time and budget, with an outstanding
attention to quality
• The QED solution is based on attention to standardization, project management, data quality and
regulatory insight that has been field tested and proven to work
• Whether you need 20 patients or 500 patients the same attention to detail will offer the
confidence that you will meet timelines with high quality
qed-clinical.com [email protected] +44 (0)1908 251 48011
QED Quality Management System
Dedicated, Highly Experienced QA Team
Robust Quality Policy
Comprehensive Audit Program and Schedule (external and internal)
Study Specific Guidelines/Manuals
Operations Manual
Induction, function specific, GCP and regulatory, Co-monitoring and Continued Professional
Development
IT- security, back-up, restoration
Disaster Recovery Plan
qed-clinical.com [email protected] +44 (0)1908 251 48012
Delivering Quality………
Local Expertise
and In-depth
Experience
Processes
and Tools
Operational
Excellence
Across the entire Study/Program
qed-clinical.com [email protected] +44 (0)1908 251 48013
Processes/Tools
Error Prevention Plan (EPP)
Lessons learnt sessions for early identification of trends
Quality Indicators Dashboard (QID)
Query trend review & corrective actions
Site issues resolutions/escalations
Recruitment acceleration
Quality Delivery Model
Site Set-up and Rapid Start-up
Dependable investigational sites
Site Assessment Visits
Rigorous training for QED/site staff
Visible management supervision
Effective start-up planning
High Quality
Data
qed-clinical.com [email protected] +44 (0)1908 251 48015
The QED Efficiency Model
Selective, coordinated and managed access to patients in countries without the cost of
infrastructure to achieve your study enrolment
Confidence from experienced project management, performance underwritten by process and
system optimisation and proof of delivery
Flexibility to complement your effort where your study has challenges and bring in immediate
local experience without having to internally coordinate local markets
Manage the peaks and troughs of the outsourced pipeline without maintaining a bench of
expensive underutilised internal resources that deflate and erode margin
Deliver the promise on time and on budget with quality that seamlessly integrates with your
study plan
qed-clinical.com [email protected] +44 (0)1908 251 48017
Meeting Your Delivery Needs
Study delivery imperatives
— Understanding feasibility – enhanced through on the ground real life experience
— Understanding project management – coordinating and leading resources to action
— Understanding quality hurdles – regulatory knowledge, data quality, timeliness
Relationship delivery imperatives
— Understanding our sponsors
— Established communication and oversight process
— Lean and efficient model with access to senior management
— Credibility and confidence through established KPI and KRI metrics
qed-clinical.com [email protected] +44 (0)1908 251 48018
QED: The Power of Partners
The heart of delivery is the ability to find and recruit the right patients and this requires
geographic scope and therapeutic experience….
28 established QED partners providing global coverage
Resource on the ground in over 50 countries
12 years average operational history
5 years average partner experience with QED
qed-clinical.com [email protected] +44 (0)1908 251 48019
QED Study Experience
Phase Total # Studies Completed *
I (including BA/BE) 296
II 371
II/III 707
III 998
IV 254
Observational /Registry 121
*Data from last 5 years
qed-clinical.com [email protected] +44 (0)1908 251 48020
QED Therapeutic Experience
Therapeutic Area
Total #
Studies
Completed *
Oncology 356
Haematology 121
Cardiology / Cardiovascular 223
Infectious Diseases 168
Immunology 63
Endocrinology /Metabolic
Disorders222
CNS (Neurology &
Psychology)265 & 157
Urology 139
Therapeutic Area
Total #
Studies
Completed*
Respiratory (incl. Allergy) 207
Gynaecology / Women’s
Health
121
Gastroenterology 158
Rheumatology 162
Dermatology 111
Pain 86
Vaccines 128
Ophthalmology 64
*Data from last 5 years
qed-clinical.com [email protected] +44 (0)1908 251 48022
Project Management Expertise
More than 120 Project Managers globally
Average of over 6 years experience in study management
Mean of 14 years in clinical research
Pharmaceutical and CRO background
Multi-discipline including Medics, Registered Nurses, Pharmacists, Scientists
Total accountability for project delivery
Primary point of contact - communication
qed-clinical.com [email protected] +44 (0)1908 251 48024
QED India – The Asia Pacific Hub
QED India HQ at Ahmedabad
Regional home based staff at
Bangalore and Trivandrum
Experience of executing large
global Phase II to IV studies in
majority of the AP Market
QED
Ahmedabad
(Office)
Regional Staff
Bangalore
Regional Staff
Trivandrum
qed-clinical.com [email protected] +44 (0)1908 251 48025
QED India is currently conducting the following:
Recruitment Acceleration and Quality Oversight in India for a global Phase IIIb/IV clinical
study - 600 patients across 06 sites
Recruitment Acceleration and Quality Oversight in India for a global Phase III clinical
study - 800 patients across 10 sites
Clinical quality assurance for a large global pharmaceutical company
Consultancy activities for an Indian medical device company
Start-up activities for a global Phase III study (feasibility and site selection)
QED India – Engagement Since Inception in
March 2012
qed-clinical.com [email protected] +44 (0)1908 251 48026
QED India - Services
Feasibility and site selection
Project Management
Clinical Monitoring & Site
Management
Quality Oversight and Site Support
Services
Clinical Data Management
Biostatistics
Safety and Pharmacovigilance
Regulatory Consulting and
Submissions
Clinical Quality Assurance
Medical Writing
qed-clinical.com [email protected] +44 (0)1908 251 48027
QED India Staff Experience
Extensive clinical monitoring, project management and quality oversight experience on global
Phase II-IV studies
Successfully delivered large complex clinical programs with high number of patients in India and
Asia Pacific region
Has experience managing high number of patient enrolment with highest data quality in
minimum time
Experience of training and working with research naïve as well as highly experienced sites
Excellent mix of local expertise enhanced with our knowledge of international regulations and
guidelines
qed-clinical.com [email protected] +44 (0)1908 251 48028
QED India – Staff Therapeutic Experience
Therapeutic Area Expertise in India
Analgesia Infectious disease
Cardiovascular Nephrology
Central Nervous System/Neurology Oncology
Dermatology Ophthalmology
Gastroenterology Respiratory
Hematology Skeletal
Immunology Vaccines
Inflammatory disease Endocrinology and Metabolic disorders
qed-clinical.com [email protected] +44 (0)1908 251 48031
The QED DifferenceQuality, Efficiency, Delivery
qed-clinical.com [email protected] +44 (0)1908 251 48032
Why QED?
Customized/flexible solutions to meet your program needs
Experienced team managing your projects
Unique Matrix driven quality delivery model to ensure deliverables are of high quality and
accepted international standards
Reliable knowledge of local requirements/regulations and hands on in-depth experience results
into operational efficiency
QED is unusual in the priority it places on satisfying our customer‘s relationship needs
Visible management involvement/supervision
High Cost efficiency
qed-clinical.com [email protected] +44 (0)1908 251 48033
Partnering together – The QED Fit
Access to patients in 50+ countries
Over 1,100 clinical experts on the ground
More than 2,700 studies successfully completed
QED are relationship specialists
QED think globally and act locally
QED believe a better partnership means better service
QED provide service with a smile
qed-clinical.com [email protected] +44 (0)1908 251 48035
OrphanReach™ is a Clinical Research Consortium consisting of local research service providers
throughout the world who are dedicated to Orphan and Rare Disease Drug Development.
Experienced professionals and organisations are consolidating their expert knowledge to provide
guidance and end-to-end solutions to sponsors who are developing rare disease treatments.
An established global infrastructure provides OrphanReach™ access to patients with rare
diseases in 50+ countries across 5 continents working with local experts who have conducted
clinical studies in a wide range of therapeutic areas.
To ensure consistent quality and standardisation, each clinical research affiliate is stringently
evaluated, selected and audited. Each affiliate follows the same quality management systems,
Standard Operating Procedures and Operations Manual globally.
Overview
qed-clinical.com [email protected] +44 (0)1908 251 48036
Structure
PROGRAM MANAGEMENT ACCOUNT MANAGEMENT
ADVISORY PANELEXECUTIVE MANAGEMENT
AFRICA MIDDLE EAST ASIA PACIFICAMERICAEUROPE
Oxford PharmaGenesis
Strategic Communications Consultancy
CRMi
Contract Research
QED Clinical Services
Contract Research
QED Clinical Services
Contract Research
QED India
Contract Research
qed-clinical.com [email protected] +44 (0)1908 251 48037
Advisory Panel
DR. MARLENE E. HAFFNERDr. Marlene E. Haffner has been involved with rare diseases for her entire medical and public health career. For 20 years she directed the Office of Orphan Products Development in the FDA. While in that position she was introduced to ARM and immediately became excited about their work and their energy. Marlene is a graduate of the George Washington University School of Medicine and the Johns Hopkins University Bloomberg School of Public Health. Her passion is making a difference in the lives of people so that their lives can be healthier and more productive. During her time with the Office of Orphan Products she oversaw the FDA approval of more than 300 products to treat rare diseases and more than 1000 in some stage of development toward FDA approval. In 2007 she was Executive Director, Regulatory Affairs at Amgen, Inc. After leaving in 2009 she formed her own consultancy company Haffner Associates.
MRS. ABBEY MEYERSMrs Abbey Meyers is the founder and President of the National Organisation for Rare Disorders (NORD), a coalition of national voluntary health agencies and a clearinghouse for information about these little known illnesses. Mrs Meyers served as the consumer representative on the National Commission on Orphan Diseases (1986-89), the NIH Human Gene Therapy Subcommittee (1989-92), the NIH Recombinant DNA Advisory Committee (RAC)(1993-96) and the FDA Biological Response Modifiers Committee (1995-99). Mrs Meyers continues to service the FDA’s Xenotransplantation Subcommittee and as an ad hoc consumer advocate for the FDA and NIH. A recipient of the FDA Commissioner’s Special Citation for Exception Dedication and Achievements (1988) and the Department of Health and Human Services award for Public Health Service for Exceptional Achievements in Orphan Drug Development (1985). Mrs Meyers holds an Honorary Doctorate from Alfred University in New York. Mrs Meyers is considered the primary consumer advocate responsible for passage of the Orphan Drug Act of 1983. She now provides consultancy services at her own consultancy firm ASM Consulting.
qed-clinical.com [email protected] +44 (0)1908 251 48040
Orphan Disease Experience
By Therapeutic Area
qed-clinical.com [email protected] +44 (0)1908 251 48041
Feature Local CRO OrphanReach “Global” CRO
Global Capabilities X ✓✓✓✓ ✓✓✓✓
Rare Disease Focus X ✓✓✓✓ X
Tailored Approach ✓✓✓✓ ✓✓✓✓ X
Pro-active Communication & Interaction ✓✓✓✓ ✓✓✓✓ X
Unbiased Site/Country Selection X ✓✓✓✓ X
Cost Effective ✓✓✓✓ ✓✓✓✓ X
High Personnel Retention ✓✓✓✓ ✓✓✓✓ X
Patient Recruitment & Retention ✓✓✓✓ ✓✓✓✓ ✓✓✓✓
Patient Advocacy Groups X ✓✓✓✓ X
Knowing KOLs ✓✓✓✓ ✓✓✓✓ ✓✓✓✓
One Contract – One Point Of Contact N/A ✓✓✓✓ ✓✓✓✓
Experienced, Dedicated Project Manager ✓✓✓✓ ✓✓✓✓ X
Site Motivation ✓✓✓✓ ✓✓✓✓ X
Benefits
qed-clinical.com [email protected] +44 (0)1908 251 48042
qed-clinical.com [email protected] +44 (0)1908 251 480
A better partnership means better customer service
Contact:
Ali Sajjad Bohra Swadhin Khawas
Country Head & Director – Clinical Operations Manager – Site Operations
Tel: +91-79-6543 1583 Mob: +91-9036 112 006
Mob: +91-9824 094 749 E-mail: [email protected]
E-mail: [email protected]
qed-clinical.com [email protected] +44 (0)1908 251 48043
QED in the Media
• Scrip Best CRO Finalists
• PharmaTimes Project Management & Recruitment Finalists
• PharmaTimes 2012 Article: „Delivering more with less“
• InPharm R&D Guide March 2012 Article: „New research alliances and the evolution of CROs“
• BioSpectrum April 2012 Article: „India to be Asia Pacific region hub for QED”
• Coverage in PharmaTimes, CenterWatch and PMLive on India Subsidiary creation
• The CRO Guide 2010: „The challenge of introducing standards in a global environment“
• The CRO Guide 2011: „Is global consistency in GCP interpretation an achieveable goal?“
• Henry Stewart Conference 2011 Presentation: „The Regulatory Requirement. Why SOPs?“
• Pharmafocus October 2011: „In Safe Hands“ - It used to be thought safe to outsource full service to the
biggest, but today many customers prefer the attention, agility and expertise of more innovative
approaches
• Pharmafocus November 2011: „Its a small world“ – Why globalisation of research is not about being big,
its about being smart
qed-clinical.com [email protected] +44 (0)1908 251 48045
Case Study – Project Delivery (1/8)
Rescue of a global phase II study in an orphan haematological indication
Study objective Study design
Challenges
An international, phase II, exploratory
dose-finding study with cohort design, in
an orphan disease indication
Safety & efficacy of a single dose (IV injection,
changed to IV infusion with amendment) medication
in various dose levels and evaluation the appropriate
dose range for future Phase III
• Rare disease, first ever recombinant pAb product in human clinical trials
• Dissatisfied Sponsor
• Demotivated sites
• Exhausted patient pool
• Quality concerns
• Particles in the IMP led to recruitment put on hold, introduction of Amendment, change
in mode of administration
qed-clinical.com [email protected] +44 (0)1908 251 48046
Case Study – Project Delivery (2/8)
Rescue of a global phase II study in an orphan haematological indication
• Efficient handling of hand-over activities.
• Re-assessment of existing sites: motivation, patient population, training on
amendment of new IMP administration
• Identification, selection and set up of additional countries and sites with expertise and
high recruitment potential
• Coordination of Amendment submission and approval in existing countries (change in
IMP administration)
• Management of recruitment for remaining cohorts and completion of LPI on schedule
qed-clinical.com [email protected] +44 (0)1908 251 48047
Case Study – Project Delivery (3/8)
Rescue of a global phase II study in an orphan haematological indication
• QED implemented risk mitigation and recruitment plans to maximize recruitment efficiency
and achieved study milestones within the agreed timelines.
• QED implemented a cohort management plan to minimize time between cohorts and overall
study timelines.
• QED added strong local and central expertise to ensure successful management of
regulatory, import and export issues in the challenging countries.
• As a result, QED managed to provide overall cost savings.
• In light of the clinical trial results, the Sponsor further considers moving into Phase III with
the product.
qed-clinical.com [email protected] +44 (0)1908 251 48048
Case Study – Project Delivery (4/8)
Rescue of a global phase II study in an orphan haematological indication
QED conducted feasibility across 5 continents, in the following countries:
- Australia - Macedonia
- Belgium - Netherlands
- Bosnia Herzegovina - Poland
- Bulgaria - Serbia
- Canada - Romania
- Croatia - South Africa
- Czech Republic - Spain
- Dubai - Turkey
- France - UK
- Germany - Russia
- Hong Kong - Ukraine
- India - USA
- Israel
- Jordan
- Lebanon
qed-clinical.com [email protected] +44 (0)1908 251 48049
Case Study – Project Delivery (5/8)
Rescue of a global phase II study in an orphan haematological indication
Identification and selection of 8 additional countries with strong local expertise and motivated
sites with good patient recruitment potential
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
This image cannot currently be displayed.
USA UK SERBIA ROMANIA UKRAINE ISRAEL INDIA RUSSIA
qed-clinical.com [email protected] +44 (0)1908 251 48050
Case Study – Project Delivery (6/8)
Rescue of a global phase II study in an orphan haematological indication
212 patients identified
during pre-screening
(database & medical
records)
41 patients
screened
28 patients
enrolled
Post-amendment, countries and sites
selected by QED identified a total of
212 potentially eligible patients during
pre-screening from their database and
medical records
41 of the pre-screened patients were
screened
28 were enrolled
qed-clinical.com [email protected] +44 (0)1908 251 48051
Case Study – Project Delivery (7/8)
Rescue of a global phase II study in an orphan haematological indication
Post-approval of the amendment, completion of the remaining cohorts and enrolment of the remaining
28 patients in 8 months as compared to enrolment of 32 patients in 15 months under the management of
the previous CRO
qed-clinical.com [email protected] +44 (0)1908 251 48052
Case Study – Project Delivery (8/8)
Rescue of a global phase II study in an orphan haematological indication
Of the 28 patients enrolled:
4 patients were recruited from the original sites
24 from the new sites selected by QED
By successful implementation of
risk/mitigation and cohort
management plans, the time
between “cohort open” and “cohort
closed” (i.e. all patients enrolled in
the given cohort) has significantly
decreased when study managed by
QED compared to the previous CRO
0
2
4
6
8
75 mcg/kg cohort (11pts)
100 mcg/kg cohort (10 pts)
125 mcg/kg cohort (10 pts)
200 mcg/kg cohort (5pts)
250 mcg/kg cohort (5pts)
250 mcg/kg cohort part 1 (2pts)
250 mcg/kg cohort part 2 (4pts)
Best dose cohort (7 pts)
qed-clinical.com [email protected] +44 (0)1908 251 48054
Case Study – Relationship Delivery
• Preferred provider for top ten pharma customer since 2008
• Total of 30 studies in critical programmes within Europe (UK, DE, HUN, FRA)
• Evolving relationship tailored to Sponsor needs
• pool of CRAs pre-trained by Sponsor during time of intensive activity
• provision of individual CRAs trained on request when Sponsor need reduced
• cost effective and flexible but trusted solution for Sponsor.
qed-clinical.com [email protected] +44 (0)1908 251 48055
Case Study: Managing a Transformational
Delivery Model
qed-clinical.com [email protected] +44 (0)1908 251 48056
Case Study – Managing a Transformational
Delivery Model (1/6)
International phase III trial in Osteoporosis
Study Design
Challenges
An international, phase III, placebo-controlled, multiple dose, parallel group, double blind study comparing
treatment in osteoporosis
• Regulatory approvals delayed due to:
• Sponsor manufacturing IMP at a
manufacturing plant which was not GMP certified
• Study design not approved by Ethics
• Disease therapy area controversial
• Previous CRO not submitting all documents
• Sponsor not having copy of submitted documents
• Transition of CRO during regulatory process
• Investigator meeting took place 2 weeks after transition of CRO
• Bulgarian regulatory authority moved offices delaying the approval
• Serious breaches at study site
• Unplanned interim analysis
qed-clinical.com [email protected] +44 (0)1908 251 48057
Case Study – Managing a Transformational
Delivery Model (2/6)
International phase III trial in Osteoporosis
Challenges Cont’d
• Communication pathways unclear, ineffective project management
• Delayed Study Start-Up and Study timelines could not be extended due to competitive drug
• No TMF for RoW countries
• Late implementation of unblinded CRAs to perform full accountability
• Limited study budget
• Change of Sponsor
• Late request to monitor screen failures
• Late decision by Sponsor to include Hungary
• For some countries outside the EU no specific regulatory timelines were available
qed-clinical.com [email protected] +44 (0)1908 251 48058
Case Study – Managing a Transformational
Delivery Model (3/6)
International phase III trial in Osteoporosis
• Introduced a highly experienced PM team for RoW countries
• Re-set communication channels and improved escalation routes
• Identified bottle necks and facilitated timelines
• Provided central regulatory support and advice to Sponsor on regulatory strategies
• Accessed established contacts with authorities via QED partners
• Fast scalability of CRA resources needed to meet aggressive monitoring timelines
qed-clinical.com [email protected] +44 (0)1908 251 48059
Case Study – Managing a Transformational
Delivery Model (4/6)
International phase III trial in Osteoporosis
• Relabeling plan drawn up and executed to prevent unblinding of IMP
• Implemented risk mitigation and recruitment plan to maximize recruitment
efficiency and achieved study milestones within the agreed timelines
• Implemented a team of unblinded CRAs to perform full accountability
• Worked efficiently within different time zones
• Managed potential serious breach, planning and executing an agreed way forward
with regulatory authorities
qed-clinical.com [email protected] +44 (0)1908 251 48060
Case Study – Managing a Transformational
Delivery Model (5/6)
0
100
200
300
400
500
600
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7
Nu
mb
er
of
Pa
tie
nts
Ra
nd
om
ise
d
Month of Recruitment
International phase III trial in Osteoporosis
Patients Randomised
Target Randomisation
qed-clinical.com [email protected] +44 (0)1908 251 48061
Case Study – Managing a Transformational
Delivery Model (6/6)
International phase III trial in Osteoporosis
• Target enrolment achieved on schedule
• Study closed on time and on agreed budget
• Potential Serious Breaches resolved without critical findings
• Study and TMF inspected by MHRA – no findings
• QED Partners exceeded expectations by delivering important regulatory advice on
issues. Costs were not covered in the Scope of Work.
• Consequently Sponsor decided that QED would be involved in MAA
qed-clinical.com [email protected] +44 (0)1908 251 48062
Global Capacity
11%
11%
21%
18%
16%
4%
19%
Access to > 1,100
Clinical Research Professionals
Senior Management (122)
Project Manager (123)
Lead/Senior CRA (249)
CRA (208)
Regulatory (186)
Quality Assurance (46)
Other (226)
qed-clinical.com [email protected] +44 (0)1908 251 48063
Capacity by Geography
MGT PM SCRA CRA Reg QA Other Total Staff
US &
Canada
36 10 30 17 1 5 3 102
South
America
2 3 4 9 1 2 9 30
Western
Europe
(WEU)
16 28 123 47 4 6 14 238
Central &
Eastern
Europe
(CEE)
33 30 49 59 80 12 6 104
Nordic/
Scandinavia
8 5 16 19 48 2 6 104
Africa &
Middle East
15 10 12 16 24 11 13 101
Asia 8 26 8 23 23 5 57 150
Russia 5 11 5 18 10 3 44 96
qed-clinical.com [email protected] +44 (0)1908 251 48064
qed-clinical.com [email protected] +44 (0)1908 251 48065